Rainbow Childrens Medicare Limited (RAINBOW) — Financial Results | 23 May 2026(3 announcements)

Rainbow Children’s Medicare reported a 24.3% YoY revenue increase to ₹4,599 crores for Q4 FY26, driven by 18% growth in inpatient discharges and 19% growth in outpatient consultations, with PAT rising 38.3% YoY to ₹782 crores. The company completed its capacity expansion phase, launching a 60-bed HRBR hospital and IVF centre in Bengaluru, while shifting focus to occupancy ramp-up and operational efficiency. Strategic projects in Coimbatore, Gurugram, and Pune advanced with new timelines, and a new asset-light hospital in Bengaluru was secured. The board proposed a 35% dividend, and cash reserves reached ₹5,942 crores to fund future capex.

Rainbow Children's Medicare announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with a recommended final dividend of [amount not verified]per share (35% on ₹10 face value), subject to shareholder approval at the upcoming AGM. The Board also re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for five years, effective August 11, 2026 to 2031, and re-appointed Dr. Dinesh Kumar Chirla as Whole Time Director for a similar term. Additionally, Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati were re-appointed as Independent Directors for second terms ending in 2031. The company fixed July 21, 2026 as the record date for dividend payment and AGM purposes. Cost Auditors Lavanya & Associates LLP were re-appointed for FY 2026-27. The AGM is scheduled for July 29, 2026 via VC/OVAM.

Rainbow Children's Medicare Limited reported FY26 revenue of ₹1,7031 crores, up 12% YoY, with net profit of [amount context mismatch] crores, up 11%, and EBITDA of [amount context mismatch] crores, up 15%, reflecting strong growth in pediatric and perinatal services across its 24-hospital network. The company highlighted expansion plans including six new hospitals and regional spokes in tier-II cities to deepen market penetration. Governance remains robust with 57 independent directors and 14 women directors on the board, supporting its mission of scalable, high-quality pediatric care.